共 49 条
[1]
Mehta S(2018)Differences in all-cause health care utilization and costs in a type 2 diabetes mellitus population with and without a history of cardiovascular disease J Manag Care Spec Pharm 24 280-290
[2]
Ghosh S(2018)Economic burden of cardiovascular disease in type 2 diabetes: a systematic review Value Health 21 881-890
[3]
Sander S(2019)Sodium-glucose cotransporter-2 (SGLT-2) inhibitors and the treatment of type 2 diabetes Annu Rev Med 70 323-334
[4]
Einarson TR(2017)Canagliflozin and cardiovascular and renal events in type 2 diabetes N Engl J Med 377 644-657
[5]
Acs A(2018)Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group Cardiovasc Diabetol 17 30-357
[6]
Ludwig C(2018)Dapagliflozin and cardiovascular outcomes in type 2 diabetes N Engl J Med 380 347-2117
[7]
Panton UH(2018)SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review Diabetologia 61 2108-2830
[8]
Kramer CK(2018)Sodium-glucose cotransporter-2 inhibitors and cardiovascular outcomes: insights from the CVD-REAL study Ann Transl Med 6 55-2597
[9]
Zinman B(2019)Empagliflozin and the risk of heart failure hospitalization in routine clinical care: a first analysis from the EMPRISE study Circulation 139 2822-1459
[10]
Neal B(2014)Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™) Cardiovasc Diabetol 13 102-3223